Illustration: Axios Visuals
Eli Lilly will acquire privately held autoimmune biotech Merida Biosciences for up to $2.88 billion, the companies announced Monday.
Why it matters: It's the latest in a series of buys this year for Lilly, which has been bulking its immunology pipeline through M&A.
